Trial Profile
Impact of Pioglitazone, Metformin and the Combination of Both on Cardiovascular Risk in Insulin-Treated Patients With Type 2 Diabetes - The PIOcomb Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms PIOcomb
- Sponsors Takeda Pharma
- 28 Apr 2012 Planned number of patients changed from 132 to 300 as reported by EudraCT.
- 28 Apr 2012 Additional trial location (Austria) identified as reported by EudraCT.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.